Get the Daily Brief
Latest Biotech News
FDA approval and adjuvant strategy for dMMR stage III colon cancer
The FDA has approved atezolizumab plus chemotherapy for adjuvant treatment of stage III dMMR colon cancer following results from the phase III ATOMIC trial. The study reported a 50% reduction in...
Biopharma dealmaking in oncology and pain
Viatris announced plans to acquire Pacira BioSciences in a $1.65 billion cash deal, strengthening its non-opioid pain portfolio with commercial-stage therapies. The transaction signals continued...
Cutting the time and complexity of Treg manufacturing via IPO-funded expansion
TRexBio priced an IPO to raise $117 million, adding momentum to a biotech window focused on immune-cell platforms. The company’s offering centers on Tregs, with the pricing highlighting continued...
Long-term in vivo BCMA CAR-T safety and durability update
EsoBiotec provided extended follow-up for its in vivo BCMA CAR-T program (ESO-T01) in relapsed or refractory multiple myeloma. Updated data through up to 15 months reported no new immunogenicity-...
Microbiome-linked mechanism for post-vaccine fever risk
A Science study tied vaccine-associated fever to gut-microbiome features, reporting that participants who developed fever after a second or third COVID-19 dose shared microbiome traits marked by...
Company pipeline signal: molecular glue collaboration in China
Roche signed a collaboration with Defand Therapeutics to discover and develop molecular glue medicines for cancer and immune-driven diseases. The reporting indicates terms could reach close to $1...
ARPA-H funding to stabilize cell therapies without refrigeration
ARPA-H launched Phase I awards under its BioStabilization Systems (BoSS) program to support room-temperature storage and shipping for cell-based biologics. The initiative will provide up to $87...
Major trial design shift: oral low-dose antiplatelet combo in minor stroke
A multicenter Chinese randomized trial found that a low-dose ticagrelor plus aspirin regimen halved early neurological deterioration in high-risk minor stroke compared with clopidogrel plus...
Advances in biosensing: magnetic tracer for sentinel node mapping in ovarian cancer
A Dutch pilot study reported that the magnetic tracer Magtrace successfully identified sentinel lymph nodes in early-stage epithelial ovarian cancer during open surgery. If validated in larger...
New cancer biomarker direction: blood proteomics to measure tumor hypoxia and predict radiotherapy benefit
A nanoparticle-enabled blood proteomics test was reported to track tumor hypoxia during radiotherapy and predict benefit in bladder cancer. The study positioned a blood-based assay as a potential...
New oncology approvals and label expansions
Bristol Myers Squibb said Zenbexus, which received FDA accelerated approval for multiple myeloma, cut the risk of disease progression by 51% versus standard therapy in a Phase 3 trial. The company...
Big pharma dealmaking in pain and China partnering
Viatris agreed to buy Pacira BioSciences for $1.65 billion, adding commercial-stage non-opioid pain treatments as generics pressure continues to reshape the pain market. The deal signals continued...
Cell therapy durability updates and the in vivo CAR-T direction
EsoBiotec provided extended follow-up on its in vivo BCMA CAR-T program ESO-T01 in relapsed/refractory multiple myeloma, reporting no new immunogenicity- or integration-related toxicities beyond...
Clinical trial readouts in solid tumors and targeted approaches
A Chinese Phase Ib/II study reported that HTMC0435, an oral PARP inhibitor, combined with temozolomide showed manageable safety and a 25% response rate in relapsed extensive-stage small-cell lung...
Diagnostic innovation in oncology imaging
A head-to-head clinical study found PSMA PET/CT detected bone metastases far more accurately than conventional bone scintigraphy in 108 prostate cancer patients, with both tested SUVmax thresholds...
FDA and regulatory oversight: SEC-FDA disclosure coordination
A newly issued SEC–FDA memorandum of understanding formalizes information-sharing channels that will intensify dual oversight of pharma and biotech disclosures. The SEC will have enhanced access...
Government funding for cell-therapy cold chain stabilization
ARPA-H launched funding under its BioStabilization Systems (BoSS) program, committing up to $87 million over four years across teams tackling room-temperature stabilization for cell-based...
Biotech IPO appetite and new market entries
TRexBio priced an IPO at $117 million for Tregs, reflecting continued investor appetite for immunology-focused platforms. The company’s offering comes alongside other recent Nasdaq debut activity...
Sequencing and diagnostics: rapid pathogen and immune profiling tools
Researchers reported that a 564-gene nanopore adaptive sampling panel can detect Parkinson’s disease variants, structural rearrangements, and repeat expansions in a single run, correctly...
Venture and startup financing in biotech-enabling tech
Vitalize secured a $31 million Series A focused on helping hospitals manage labor and capacity, positioning the product around operational scheduling rather than clinical workflows. The round was...